Urteste Expands Development of Innovative Diagnostic Projects
September 26, 2024 10:29 ET
|
Urteste S.A.
Urteste Expands Development of Innovative Diagnostic Projects Gdańsk, Poland – 26 SEPTEMBER 2024, 16:00 CET - Urteste S.A. (Warsaw Stock Exchange: URT), a biotechnology company...
EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy
September 26, 2024 07:00 ET
|
EnnoDC
PRESS RELEASE EnnoDC unveils the next generation of dendritic cell-targeting immunotherapies supported by new leadership and an evolved strategy Versatile new technology featuring an...
AB Science fait aujourd'hui le point sur le programme microtubule AB8939 et en particulier sur la capacité d'AB8939 à générer une réponse sur le réarrangement du gène MECOM
September 26, 2024 02:28 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LE PROGRAMME MICROTUBULE AB8939 ET EN PARTICULIER SUR LA CAPACITÉ D’AB8939 À GÉNÉRER UNE RÉPONSE SUR LE REARRANGEMENT DU GENE MECOM Paris, 26...
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
September 26, 2024 02:28 ET
|
AB Science
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE MICROTUBULE PROGRAM AB8939 AND IN PARTICULAR THE ABILITY OF AB8939 TO GENERATE RESPONSE ON MECOM REARRANGEMENT Paris, 26 September 2024, 8.30am CET...
PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics
September 19, 2024 09:00 ET
|
Renovaro Inc
AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven,...
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
September 19, 2024 08:00 ET
|
AIM ImmunoTech Inc.
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues to be generally well-tolerated with no...
KnitWell Group Supports the Breast Cancer Research Foundation With Eight Iconic American Retail Fashion Brands Through Their Sisterhood of Strength Campaign
September 18, 2024 15:25 ET
|
D S Simon
NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- In honor of Breast Cancer Awareness Month, a leading multi-brand retail operating company, KnitWell Group, comprised of Ann Taylor, Chico’s, Haven Well...
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
September 18, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
September 18, 2024 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction Chemotherapy Treatment ICT01,...
Wistar Institute Researchers Identify Parkinson-related Protein’s Role in Cancer and T Cell Activation
September 17, 2024 12:54 ET
|
The Wistar Institute
PHILADELPHIA, PA, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Wistar Institute’s President and CEO, Dario C. Altieri, M.D., and team have demonstrated the role of Parkin — a protein implicated in...